Index

A
AAHA (American Animal Hospital Association), 100
Absorption, of chemotherapeutics, 69
Acitretin (Neotigason or Soriatane), 85
Actinomycin D
drug information, 301
extravasation injury from, 202, 203, 205
Active listening, 143–144
Acupuncture, 91, 91f, 107
Acute renal failure, 208–212
causes, 208, 209–210
clinical features, 210–211
diagnosis, 209, 211–212
treatment/management, 209, 212
ACVECC (American College of Veterinary Emergency and Critical Care), 8
ACVIM (American College of Veterinary Internal Medicine), 7, 8
ACVR (American College of Veterinary Radiology), 8
ACVS (American College of Veterinary Surgery), 8
ACVS-CA (Australian College of Veterinary Scientists), 7
Adaptive therapy, 106–107
Airedale terrier, doxorubicin cardiotoxicity in, 75t
Alanine aminotransferase (ALT), evaluation in staging of cancer, 29–30
Albumin, evaluation in staging of cancer, 31
Alendronate, 104–105
Alkaline phosphatase (ALP), evaluation in staging of cancer, 30, 252, 253
Allergic reactions, 76, 195–201
Alpha2-agonists, 106
Alternative therapy. See Complementary and alternative medical (CAM) therapies
Aluminum hydroxide, for hyperphosphatemia, 193t
American Animal Hospital Association (AAHA), 100
American College of Veterinary Emergency and Critical Care (ACVECC), 8
American College of Veterinary Internal Medicine (ACVIM), 7, 8
American College of Veterinary Radiology (ACVR), 8
American College of Veterinary Surgery (ACVS), 8
American Physical Therapy Association, 108
American Veterinary Medical Association, 108
Aminobisphosphonates, 104, 255
Amoxicillin-clavulanic acid, 294t
Amputation, 51–52, 53f, 54f
for bone pain management, 102, 103f
for osteosarcoma, 234
for soft tissue sarcoma (STS), 246
Analgies
administration by veterinary nurses, 98
adverse effects, monitoring and treating, 98
doses of commonly used analgesics, 290t–291t
Anaphylaxis, 195–201
causes, 76, 195–196, 197
clinical features, 196f, 197, 200
diagnosis, 196, 197f, 200
treatment/management, 196–197, 198t–199t, 201
Anemia, 28–29
causes, 161, 162–163
clinical features, 162–163
diagnosis, 162, 163–164
myelosuppressive chemotherapy and, 72, 124
nonregenerative, 161
regenerative, 161
treatment/management, 162, 162f, 164
Antiangiogenesis, 86–87, 250
Antibiotics
dose route and interval, 294t
for febrile neutropenia, 171–174
prophylactic therapy, 125, 250
for secondary infection in chronic lymphoid leukemia, 283
for sepsis, 127
Antiemetics, 116, 292t
Antihistamine, for anaphylaxis, 197, 198t
Antioxidants, dietary, 92
Aortic body tumor, pericardial effusion in, 222
Apoptosis, 190
Appetite stimulants, 117, 293t
Aquatic therapy, 110
Arginine supplementation, 115
Assisted feeding, 117, 118f
Australian College of Veterinary Scientists (ACVSc), 7
Avastin, 87

B
Balance boards, 110
BCNU, 301
Bernese mountain dog, malignant histiocytosis in, 10
Bevacizumab, 87
Bile acids, evaluation in staging of cancer, 39
Bilirubin, evaluation in staging of cancer, 30
Biochemistry panel, use in staging of cancer, 29–31
alanine aminotransferase (ALT), 29–30
albumin, 31
alkaline phosphatase (ALP), 30
calcium, 30–31
creatinine, 30
globulin, 31
glucose, 31
urea, 30
Biological response modifiers (BRMs), 85–88
antiangiogenesis, 86–87
differentiating agents, 85–86
functions of, 85
imiquimod cream (Aldara), 87
immunotherapy, 87–88
piroxicam, 86
tyrosine-kinase inhibitors, 88
Biopsy. See also Histopathology
needle core (Tru-cut), 20, 20f, 21f
safety of, 20
sample fixation, 20, 22
surgical, 20, 48–49
Bisphosphonate therapy, 106, 179, 255
Bladder cancer. See Transitional cell carcinoma (TCC)
Blankets, 107
Bleomycin, 301
Blood culture, 171–172
Body condition, assessment of, 115
Body surface area (BSA)
chemotherapy dose calculation, 68
conversion chart for cats, 288t–289t
conversion chart for dogs, 287t–288t
Bond, human-animal, 135–136, 136f
Bone emergencies, 217–221
hypertrophic osteopathy, 218–221
pathological fracture, 217–218
Bone marrow
myelosuppression from chemotherapeutics, 72–73
radiation therapy, nursing care after, 65–66
Bone pain, 102, 254–255
Bone sarcoma. See Osteosarcoma
Bone scintigraphy, 38
Boundaries, maintaining professional, 151
Boxer
doxorubicin cardiotoxicity, 75t
osteosarcoma, 103f, 254f
Brachytherapy, 59, 59f
Brain surgery, 55, 56f
Breed predilections. See specific breeds
BRMs. See Biological response modifiers (BRMs)
BSA. See Body surface area (BSA)
Buprenorphine, 106, 291t
Burnout, 152
Butorphanol, 106, 116, 291t, 292t
C
Cachexia, 113–115, 114f
Calcitonin, for osteoclast inhibition, 179, 192t
Calcium
evaluation in staging of cancer, 30–31
hypercalcemia, 175–180, 192t, 208
hypocalcemia, 193t
serum calcium levels, 176–177
Calcium gluconate
for hyperkalemia, 191, 193t, 212
for hypocalcemia, 193t
Calcium nephropathy, 177, 208
Calipers, 27, 28f
CAM. See Complementary and alternative medical (CAM) therapies
Cancer cachexia, 113–115, 114f
Cancer, defined, 5
Cancer diagnosis, impact of, 135
Carboplatin
“delayed” neutrophil nadir with, 125
drug information, 302
for mammary carcinoma in cats, 270
for oral squamous cell carcinoma, 261
for osteosarcoma, 70–71, 254
thrombocytopenia from, 124
urinary excretion of, 84
Carcinoma, 5. See also Mammary carcinoma; Pulmonary carcinoma; Squamous cell carcinoma; Transitional cell carcinoma
Cardiac dysfunction, staging of cancer and, 26–27
Cardiac tamponade, 222–225
Cardiotoxicity, of chemotherapeutics, 73, 75t
Carprofen, 290t, 291t, 292t, 293t
Chemicals, as environmental carcinogens, 11
Chemodectoma, pericardial effusion in, 222
Chemodectomas, pericardial effusion in, 222
Chemodectomas, pericardial effusion in, 222
Chemodectoma, pericardial effusion in, 222
Chemodectomas, pericardial effusion in, 222
Chemotherapy, 67–84. See also specific drugs

- adjuvant, 71
- clinical examples, 70–71
- decision tree for intravenous administration, 80f
- dose calculation, 68
- dose intensity, 68
- drug handling, safe, 80–83, 81f–82f
- drugs, quick reference to, 301–305
- excreta from patients, handling, 83–84
- health and beauty care during, 72
- how it works, 67
- intravenous bolus injections, 83
- intravenous infusions, 83
- neoadjuvant, 71
- pharmacokinetics and pharmacodynamics, 69–71
- absorption, 69
- distribution, 69
- excretion, 70–71
- metabolism, 71
- PhaSeal system, 79, 79f, 82–83
- phases of, 233–234
- consolidation, 233
- induction, 233
- maintenance, 233–234
- rescue therapy, 234, 235

for specific cancers
- chronic lymphoid leukemia (CLL), 282, 283
- hemangiosarcoma, 250
- lymphoma in cats, 238, 239
- lymphoma in dogs, 233–234, 235
- mammary carcinoma in cats, 270
- mammary carcinoma in dogs, 267, 268
- mast cell tumor, 242
- melanoma, 258, 259
- oral squamous cell carcinoma, 261
- osteosarcoma, 254
- pulmonary carcinoma, 279
- soft tissue sarcoma (STS), 247
- transitional cell carcinoma (TCC), 275

staging of cancer, influence on, 26

strategies
- chemotherapy drug resistance, 69
- combination chemotherapy, 69
- tumor size and, 68

timing of, 71

tips, 77–80, 78f–80f

toxicity
- cardiotoxicity, 73, 75t
- gastrointestinal toxicity, 73
- hair and coat changes, 76, 76f–77f
- immune-mediated toxicity, 75–76
- myelosuppression, 72–73
- tissue differences, 67
- urologic toxicity, 75

Children
- euthanasia decision/process, involvement in, 130
- grief and loss, 141
- Chlorambucil, for chronic lymphoid leukemia, 282, 283
- Chronic lymphoid leukemia (CLL), 281–283
- case example, 283
- nursing highlights, 282–283
- overview of, 281
- staging, 281–282, 282f
- treatment, 282
- Cisplatin
- drug information, 302
- nephrotoxicity, 75, 208–209
- for osteosarcoma, 70, 254
- urinary excretion of, 84

C-kit proto-oncogene, 88

Clichés, avoiding, 144

Clinical remission, 233
- CLL (chronic lymphoid leukemia), 281–283
- Coagulopathy, 157. See also Disseminated intravascular coagulation (DIC)
- Cobalt, radioactive, 58
- Cocker spaniel, doxorubicin cardiotoxicity in, 75t
- Codeine, 63, 104, 255, 291t
- Cold therapy, 111
- Colitis, hemorrhagic after doxorubicin administration, 73
- Colon, nursing care after radiation therapy, 65
- Comfort, 151

Communication with owners, 6–7, 142–146
- communication network, 145
- on complementary and alternative medical (CAM) therapies, 92–93
- conflict, dealing with, 145–146
- importance of good, 143
- improving communications, 143
- obstacles to communication, 145
- useful skills, 143–145, 144t
- active listening, 143–144
- asking open questions, 144
- avoiding clichés, 144
- empathy, 143, 144t

Compassion, 138
- Compassion fatigue, 152
- Complaints about colleagues, 151
- Complementary and alternative medical (CAM) therapies, 90–93, 107
- Complete blood count (CBC)
- changes associated with cancer treatment, 123–125
- evaluation at time of chemotherapy treatment, 72–73, 74f, 77
- evaluation in staging of cancer, 27–29
- platelet assessment, 166

Complete response, defined, 46t

Computed tomography (CT)
- hypoglycemia, 183
- staging of cancer, 34–36, 35f–38f

Confidentiality, 151

Conflict
- in cancer-care team, 148–149
- in nurse-owner relationship, 145–146
- between owners, 150
- Conjunctivitis, after radiation therapy, 63
- Consolidation phase, of chemotherapy, 233

Corticosteroids
- in multimodal pain management, 104
- for osteosarcoma pain, 255

Cost of treatment, 149

Counseling, 141, 153

Creatinine clearance, evaluation in staging of cancer, 38–39

Creatinine, evaluation in staging of cancer, 30

CT. See Computed tomography (CT)

Cyclooxygenase, 106

Cyclophosphamide
- drug information, 302–303
- hemorrhagic cystitis, 75, 214
- for lymphoma in cats, 238
- for lymphoma in dogs, 233

Cyproheptadine, for appetite stimulation, 117, 293t
Cystitis, 31, 75, 214
Cytology
advantages of, compared to histopathology, 16
fine-needle aspiration (FNA), 17, 18
impression smears (“touch-prints”), 17, 19, 19f
lymphoma in cats, 236, 237f
objectives of, 17
staining process, 19
Cytopathology, 15. See also Cytology
Cytoreduction, 49
Dacarbazine, 303
Dalmatian, doxorubicin cardiotoxicity in, 75f
Dancing, 110
D-dimer assay, 158
Death of pet
euthanasia, 129–132

grief and loss
children, 141

counseling, 141
elderly owners, 141–142

how nurses can help, 138–140

memorials, 142

owner reactions to, 137–138

societal attitudes toward, 140

pet remains, dealing with, 130
Debulking, 49, 51f
Delta receptors, 105
Deracoxib, 290t
Dermatitis, following radiation therapy, 61f
Desquamation, moist, 62, 62f
Dexamethasone
for anaphylaxis, 197, 198t
for hypercalcemia, 192t
Dexrazoxane, for doxorubicin extravasation injury, 205, 206
Dextrose
for hyperkalemia, 191, 193t
for hypoglycemia, 182, 192t
Diagnosis of cancer, 15–24
definition of pathology terms, 16
impact on owners, 135
overview, 15
tumor cytology, 17–19, 18f–19f
tumor histopathology, 19–24, 20f–21f, 23f–24f
Diarrhea, 121
Diazepam, for appetite stimulation, 117, 293t
Diazoxide, for hypoglycemia, 182, 184, 192t
DIC. See Disseminated intravascular coagulation (DIC)
Differentiating agents, 85–86
Dimethylsulfoxide (DMSO), for doxorubicin extravasation injury, 206
Diphenhydramine
for anaphylaxis, 197
for mast cell tumor, 243
Disseminated intravascular coagulation (DIC), 157–161
causes, 159
clinical features, 159
diagnosis, 157–158, 159–160
treatment/management, 158, 160
Distribution, of chemotherapeutics, 69
DNA vaccination, 88
Doberman pinscher, doxorubicin cardiotoxicity in, 73, 75t
Documentary, 151

dogs
body surface area (BSA) conversion chart, 287t–288t
cancers in
lymphoma, 229–235
mammary carcinoma, 264–272

mast cell tumor, 240–243
oral melanoma, 256–259
osteosarcoma, 252–255
pulmonary carcinoma, 277–280

soft tissue sarcoma, 244–247
splenic hemangiosarcoma, 248–251

transitional cell carcinoma, 273–276

drug dosages

analgesics, 290t–291t

antibiotics, 294t

antiemetics, 292t

appetite stimulants, 293t

gastroprotectants, 293t
Dolasetron, 116, 292t
Dopamine
for acute renal failure, 212
for anaphylaxis, 199t
for calciuresis, 179
Doxorubicin
drug information, 303
excretion of, 84
for hemangiosarcoma, 250, 251
for lymphoma in cats, 238
for lymphoma in dogs, 233
for mammary carcinoma in cats, 270
for oral squamous cell carcinoma, 261
for osteosarcoma, 254, 255
toxicity
anaphylaxis, 195–196

cardiotoxicity, 73, 75t

extravasation injury, 202–206, 204f, 205f

hemorrhagic colitis, 73

hypersensitivity reactions, 75

inappetence, 121

nausea and inappetence, 121

nephrotoxicity, 75, 208

Doxycycline, 87
Drug resistance, chemotherapy, 69
DTIC, 303

E
EACA (epsilon aminocaproic acid), 168
Ears, nursing care after radiation therapy, 63
ECG
acute renal failure, 211
anaphylaxis, 200
febrile neutropenia, 173
hypercalcemia, 179
hyperkalemia, 211
hypokalemia, 186–187
hypomagnesemia, 189
pericardial effusion, 225

peritoneal dialysis, 211

tumor lysis syndrome (TLS), 191
Echocardiography
febrile neutropenia, 173
pericardial effusion, 225
staging of cancer and, 26

ECVIM (European College of Veterinary Internal Medicine), 7
Edema, facial, 195, 196f
Elderly pet owners, pet loss and, 141–142
Electrical stimulation, 111
Electron beam teletherapy, 58, 59f

Emergencies
  anaphylaxis, 195–201
  bone, 217–221
  febrile neutropenia, 170–174
  hematologic, 157–169
  metabolic, 175–194
  pericardial effusion and cardiac tamponade, 222–226
  urological, 208–216

Emotional experience, of nurses, 148–153
  cancer-care team, 148–149
  counseling, 153
  ethical dilemmas, 148–152
  self-care, 152
  stress, 152–153

Empathy, 143, 144t

End-of-life patient care, 132

Endotoxemia, 170

Environmental carcinogens, 10–12

Environmental tobacco smoke (ETS), 10–12, 11f

Epidemiology, and cancer, 9

Epinephrine, for anaphylaxis, 197, 198t, 199t

Epsilon amino acid (EACA), 168

Erythrocytes
  anemia, 72, 161–164
  life span, 161

Erythropoiesis, 29

Esophagostomy tubes, 119

Feline leukemia virus (FeLV), 236

Fentanyl transdermal patch, 104, 106, 255, 291t

Fever
  defined, 170
  neutropenic, 170–174

Fibrosarcoma, 244. See also Soft tissue sarcoma (STS)

Fine-needle aspiration (FNA)
  description of process, 17, 18f
  lymph node evaluation, 32

Fish-oil supplements, 115

Fixation, of biopsy samples, 20, 22

Flat-coated retriever, malignant histiocytosis in, 10

Flea-control products, as cancer risk factor, 11–12, 260

Formalin, 20, 22

Fracture, pathological
  causes, 217–218
  clinical features, 218
  diagnosis, 217, 218
  treatment/management, 217, 218

Furosemide
  for acute renal failure, 212
  for calciuresis, 179, 192t

Gastrointestinal support
  medications, 115–117
  antiemetics, 116, 292t
  appetite stimulants, 117, 293t
  gastroprotectants, 116–117, 293t
  side effects of chemotherapy, 121
  strategies in critically ill cancer patients, 120–121

Gastrointestinal toxicity, of chemotherapeutics, 73, 121

Gastroprotectants, 116–117, 293t

Gastrostomy tube, 65, 119

Gemcitabine, 303

Gentamicin, 294t

German shepherd dog
  cutaneous fibrosarcoma, 10
  cystadenocarcinoma, 10

Globalin, evaluation in staging of cancer, 31

Glossary, 296–300

Gloves, latex, 80, 81f

Glucagon, for hypoglycemia, 192t

Glucocorticoids
  for anaphylaxis, 197, 198t
  for hypercalcemia, 179, 192t
  for hypoglycemia, 182, 184, 192t
  osteoclast inhibition, 179

Glucose
  evaluation in staging of cancer, 31
  hypoglycemia, 180–184, 192t

Glutamine supplementation, 115

Gonadectomy, effect on cancer risk, 10

Grading of tumors
  by histopathology, 22–23
  lymphoma in cats, 237–238
  mast cell tumors, 240, 241f
  soft tissue sarcoma (STS), 244–245

Granulocyte colony stimulating factor (G-CSF), 127–128, 172

Febrile neutropenia, 170–174
  causes, 172
  clinical features, 172–173
  diagnosis, 171–172, 173
  treatment/management, 172, 173–174

Feeding
  assisted, 117, 118f
  parenteral, 119–120

Feline leukemia virus (FeLV), 236

Fentanyl transdermal patch, 104, 106, 255, 291t

Fever
  defined, 170
  neutropenic, 170–174

Fibrosarcoma, 244. See also Soft tissue sarcoma (STS)

Fine-needle aspiration (FNA)
  description of process, 17, 18f
  lymph node evaluation, 32

Fish-oil supplements, 115

Fixation, of biopsy samples, 20, 22

Flat-coated retriever, malignant histiocytosis in, 10

Flea-control products, as cancer risk factor, 11–12, 260

Formalin, 20, 22

Fracture, pathological
  causes, 217–218
  clinical features, 218
  diagnosis, 217, 218
  treatment/management, 217, 218

Furosemide
  for acute renal failure, 212
  for calciuresis, 179, 192t

Gastrointestinal support
  medications, 115–117
  antiemetics, 116, 292t
  appetite stimulants, 117, 293t
  gastroprotectants, 116–117, 293t
  side effects of chemotherapy, 121
  strategies in critically ill cancer patients, 120–121

Gastrointestinal toxicity, of chemotherapeutics, 73, 121

Gastroprotectants, 116–117, 293t

Gastrostomy tube, 65, 119

Gemcitabine, 303

Gentamicin, 294t

German shepherd dog
  cutaneous fibrosarcoma, 10
  cystadenocarcinoma, 10

Globalin, evaluation in staging of cancer, 31

Glossary, 296–300

Gloves, latex, 80, 81f

Glucagon, for hypoglycemia, 192t

Glucocorticoids
  for anaphylaxis, 197, 198t
  for hypercalcemia, 179, 192t
  for hypoglycemia, 182, 184, 192t
  osteoclast inhibition, 179

Glucose
  evaluation in staging of cancer, 31
  hypoglycemia, 180–184, 192t

Glutamine supplementation, 115

Gonadectomy, effect on cancer risk, 10

Grading of tumors
  by histopathology, 22–23
  lymphoma in cats, 237–238
  mast cell tumors, 240, 241f
  soft tissue sarcoma (STS), 244–245

Granulocyte colony stimulating factor (G-CSF), 127–128, 172
Great Dane, doxorubicin cardiotoxicity in, 75t
Grief and loss
children, 141
  counseling, 141
elderly owners, 141–142
  how nurses can help, 138–140
memorials, 142
owner reactions to, 137–138
  professional boundaries, maintaining, 151
societal attitudes toward, 140
stages, 137

H
H2 blocker
  for anaphylaxis, 199t
  as gastroprotectant, 117
  for mast cell tumors, 242–243
Hair and coat changes from chemotherapeutics, 76, 76f–77f
Handling of chemotherapy drugs, 80–83, 81f–82f
Heat therapy, 111
Hemangiopericytoma, 244. See also Soft tissue sarcoma (STS)
Hemangiosarcoma
case example, 250–251
  metastatic, 32f
  nursing highlights, 250
  overview of, 248
  splenic, 248–251
  staging, 248, 249f, 250–251
  treatment, 249–250, 249f
Hematologic emergencies, 157–169
  anemia, 161–164
  disseminated intravascular coagulation (DIC), 157–161
  thrombocytopenia, 164–169
Hematologic support, 123–128
Hemangiosarcoma
case example, 250–251
metastatic, 32f
nursing highlights, 250
overview of, 248
pericardial effusion in, 222
splenic, 248–251
staging, 248, 249f, 250–251
thrombocytopenia in, 163
treatment, 249–250, 249f
Hematologic emergencies, 157–169
  anemia, 161–164
  disseminated intravascular coagulation (DIC), 157–161
  thrombocytopenia, 164–169
Hematologic support, 123–128
Hematoma, spread of cancer cells and, 48
Hematopoietic tumors, defined, 5
Hematuria, 213–216
  causes, 213–215
  clinical features, 213, 215
  diagnosis, 213f, 214, 215
  treatment, 214, 215–216
Hemoglobin, 161
Hemogram, evaluation at time of chemotherapy treatment, 72–73, 74f
Hepin, 158, 165
Hepatic dysfunction, chemotherapy and, 26
Herbal medicines, 90–92
HHM (humoral hypercalcemia of malignancy), 175
Histamine, release in anaphylaxis, 195–196
Histocytosis, immunotherapy for, 87
Histopathology
  advantages of, compared to cytology, 16t
  description, 19–22
  grading and staging of tumors, 22–23
  margins, evaluation of tumor, 23, 23f, 24f
  questions answered by, 22
  special stains, 24
HO. See Hypertrophic osteopathy
Homeopathy, 92
Hospice care, 132
Human-animal bond, 135–136, 136f
Humoral hypercalcemia of malignancy (HHM), 175
Hyaluronidase, for vincristine extravasation injury, 203f, 205, 207
Hypercalcemia, 175–180
  causes, 175–176, 177
  clinical features, 178, 208
  defined, 175
  diagnosis, 176, 178–179
  treatment, 176–177, 179–180, 192t
Hyperkalemia, 190–191, 193t, 211
Hyperparathyroidism, 176
Hyperphosphatemia, 193t
Hypersensitivity reactions, to chemotherapeutics, 75–76
Hypertrophic osteopathy (HO), 218–221
  causes, 218, 220
  clinical features, 218–219, 220–221
  diagnosis, 219, 221
  treatment, 219, 221
Hypocalcemia, 193t
Hypoglycemia, 180–184
  causes, 180–181, 182
  clinical features, 183
  diagnosis, 181, 183
  treatment, 181–182, 184, 192t
Hypokalemia, 184–187
  causes, 185, 186
  clinical features, 185, 186
  diagnosis, 185, 186–187
  treatment, 185, 187, 193t
Hypomagnesemia, 187–189
  clinical features, 188–189
  diagnosis, 187–188, 189
  treatment, 188, 189
Imatinib, 88
Idiopathic thrombocytopenia purpura (ITP), 165
Ilosfamide
  drug information, 304
  toxicity
    anaphylaxis, 196
    hemorrhagic cystitis, 214
Imaging
  acute renal failure, 211–212
  anaphylaxis, 200
  anemia, 164
  disseminated intravascular coagulation (DIC), 160
  febrile neutropenia, 173
  hemangiosarcoma, 248, 249f, 250–251
  hematuria, 215
  hypercalcemia, 179
  hypoglycemia, 183
  lymphoma in dogs, 232–233, 232f
  mammary carcinoma in dogs, 265f, 268
  osteosarcoma, 233f
  pathologic fracture, 218
  pericardial effusion, 223, 223f, 225
  staging of cancer, 32–38
  bone scintigraphy, 38
  computed tomography (CT), 34–36, 35f–38f
  magnetic resonance imaging (MRI), 35–36
  radiography, 32, 32f, 33f, 34
  ultrasonography, 34, 34f
  thrombocytopenia, 168
  transitional cell carcinoma (TCC), 273, 274f, 276
  tumor lysis syndrome (TLS), 191
Imatinib, 88
Imipenem, 294t
Imiquimod cream (Aldara), 87
Immune-mediated thrombocytopenia (IMT), 165
Immune-mediated toxicity, of chemotherapeutics, 75–76
Immunohistochemistry, 24
Immunotherapy, 87–88
Impression smears (“touch-prints”), 17, 19, 19f
Incline/decline exercise, 109
Induction phase, of chemotherapy, 233
Infection
in febrile neutropenia, 170–172
thrombocytopenia from, 165, 167
urinary tract, 31, 273, 276
Injection site sarcoma, 244
Insecticides, as cancer risk factor, 11–12
Instrument packs, changing, 55
Insulin, for hyperkalemia, 191, 193t, 212
Insulinoma, 180–181
International Veterinary Academy of Pain Management (IVAPM), 100, 101
Internists, 8
Intracapsular surgery, 49, 51f
Iodide, radioactive, 59–60
Irish wolfhound, doxorubicin cardiotoxicity in, 75t
Isocad, 92
Isoproterenol, for anaphylaxis, 199t
Isotretinoin (Accutane), 85
ITP (idiopathic thrombocytopenia), 165

J
Jejunostomy tubes, 119
Joints, assessment of, 108–109

K
Kaolin, 121
Kaplan-Meier survival curve
description of, 47, 47f
lymphoma in dogs, 230f
mammary carcinoma in dogs, 265f
mast cell tumors, 240
melanoma, 257f
osteosarcoma, 253f
pulmonary carcinoma, 278f
soft tissue sarcoma (STS), 246f
transitional cell carcinoma (TCC), 275f
Kappa receptors, 105
Karo syrup, for hypoglycemia, 192t
Keratoconjunctivitis sicca, after radiation therapy, 63
Ketoprofen, 290t

L
Laboratory findings
acute renal failure, 211
anaphylaxis, 200
anemia, 163–164
disseminated intravascular coagulation (DIC), 159–160
febrile neutropenia, 173
hematuria, 215
hypercalcemia, 178
hypoglycemia, 183
hypokalemia, 186
hypomagnesemia, 189
pericardial effusion, 225
thrombocytopenia, 168
tumor lysis syndrome (TLS), 191
L-asparaginase
anaphylaxis with, 76, 195
drug information, 304
for lymphoma in dogs, 233
Leash walking, 109
Leukemia
acute renal failure in, 208
chronic lymphoid leukemia (CLL), 281–283
complete blood count and staging of, 29
defined, 5
tumor lysis syndrome (TLS), 190, 191
Lidocaine, for post-radiation pain relief, 65
Limb amputation, 51–52, 53f, 54f
Limb function, assessment of, 108–109
Linear accelerator, 59
Linoleic acid, 85–86
Listening, active, 143–144
Lomustine
drug information, 302
thrombocytopenia from, 124
Lung cancer. See Pulmonary carcinoma
Lymph node
evaluation in staging of cancer, 32
measurements, 27, 28f, 28t
Lymphocytes, in chronic lymphoid leukemia, 281–282, 282f
Lymphoma
acute renal failure in, 208
in cats, 236–239
case example, 239
grading, 237–238
nursing highlights, 238–239
overview of, 236–238, 237f
prognosis, 237–238
staging, 237, 239
treatment, 238
combination therapy, 69
defined, 5
in dogs, 229–235
case example, 235
diagnosis, 229–233, 232f
nursing highlights, 230, 232
overview of, 229
prognosis, 229–231, 230f
staging, 231f, 233, 235
treatment, 233–234
gastrointestinal supportive care, 120–121
risk factors, 11
thrombocytopenia in, 165
tumor lysis syndrome (TLS), 190, 191
Lymphosarcoma. See Lymphoma

M
Magnesium
hypomagnesemia, 187–189, 193t
serum levels, normal, 187
Magnesium chloride, 188, 189, 193t
Magnesium sulfate, 188, 189, 193t
Magnetic resonance imaging (MRI), use in staging of cancer, 35–36
Maintenance phase, of chemotherapy, 233
Malignant fibrous histiocytoma, 244. See also Soft tissue sarcoma (STS)
Mammary carcinoma
in cats, 269–272
appearance, 270f
case example, 272
metastasis, 269, 270, 272
nursing highlights, 271
overview of, 269
treatment, 270–271, 271f
in dogs, 264–268
case example, 267–268
metastasis, 264, 265f
nursing highlights, 267
overview of, 264
prognostic factors, 267
of wide (excisional) surgery, 49f, 50–51
Mast cell tumor (MCT)
case example, 243
diagnosis, 241–242, 241f–242f
grade, 240, 241f
mitotic index and predicted survival, 240
nursing highlights, 242–243
overview of, 240
staging, 241–242, 241f, 243
mean survival time, 247
median survival time, 247
Maxillectomy, 52–54
MDR-1 gene (multiple drug resistance) test, 39
Mean survival time, 47
Median survival time, 47
Medical history, obtaining from owner, 6
Megavoltage teletherapy, 58
Megestrol acetate, for appetite stimulation, 117, 293t
Melanoma
appearance of, 256, 257f
case example, 259
DNA vaccination, 88
metastasis, 256, 258
oral in dogs, 256–259
nursing highlights, 258
overview of, 256
staging, 256, 257f, 258
Megavoltage teletherapy, 58
Meloxicam, 103, 290t
Melphalan, 304
Memorials, 142
Meningioma, 55, 56f
Mesna, 75
Mesothelioma, 11, 222
Metabolic alkalosis, from hypokalemia, 185
Metabolic emergencies, 175–194
hypercalcemia, 175–180, 192t
hyperkalemia, 193t
hyperphosphatemia, 193t
hypocalcemia, 193t
hypoglycemia, 180–184, 192t
hypokalemia, 184–187, 193t
hypomagnesemia, 187–189, 193t
tumor lysis syndrome (TLS), 190–191
Myeloma, thrombocytopenia in, 165
Myelophthisis, 29
Myelosuppression
anemia with, 124, 161
chemotherapeutic agents, relative effects of, 124t
description, 72–73, 123
neutropenia with, 72–73, 124–128, 170–172
thrombocytopenia with, 73, 124, 165
Nasal carcinoma, CT scan evaluation of, 36f–37f
Necrosis, with extravasation injury, 202–203, 204f
Needle core (Tru-cut) biopsy, 20, 20f, 21f
Nephrotoxicity
calcium nephropathy, 177, 208
cisplatin, 75, 208–109
doxorubicin, 75, 208
streptozotocin, 208–209
Neupogen, 172
Neurofibrosarcoma, 244. See also Soft tissue sarcoma (STS)
Neutering, effect on cancer risk, 10
Neutropenia
febrile, 174
managing neutropenic patients, 126–127
marked (grade 3), 126
mild (grade 1), 126
moderate (grade 2), 126
severe (grade 4), 126–127
Neuropathy
Neutrophils
  absolute count, 72, 124
  assessment by blood smear, 171, 171f
  evaluation at time of chemotherapy treatment, 72–73, 74f, 77
  febrile neutropenia, 170–174
  postchemotherapy nadir of, 72, 77, 170
Newfoundland, doxorubicin cardiotoxicity in, 75t
Nonsteroidal antiinflammatory drugs (NSAIDs)
  doses of commonly used, 290t–291t
  mode of action, 105–106
  in multimodal pain management, 103–104
  for osteosarcoma pain, 255
  use in cats, 106
Nosectomy, 54–55, 55f
Nutrition, as cancer risk factor, 9–10
Nutritional supplements, 90–92
Nutritional support
  assisted feeding, 117, 118f
  body condition, assessment of, 115
  cancer cachexia, 113–115, 114f
  dietary guidelines, 115
  feeding tubes, 117–119
  gastrointestinal side effects of chemotherapy, 121
  gastrointestinal supportive medications, 113–117
  antiemetics, 116
  appetite stimulants, 117
  gastroprotectants, 116–117
  Ogilvie’s Homemade Cancer Food (recipe), 116f
  parenteral feeding, 119–120
  strategies for critically ill cancer patient, 120–121
Obesity, 114, 114f
Octreotide, for hypoglycemia, 184, 192t
Omega-3 fatty acid supplementation, 115
Omeprazole, 117, 243, 293t
Ondansetron, 116, 292t
Open questions, asking, 144
Opioid receptor types, 105
Opioids
  description of, 104, 105
  doses of commonly used, 291t
  for osteosarcoma pain, 255
  table of commonly used, 105f
  use in cats, 106
Oral cavity
  melanoma, 256–259
  radiation therapy, nursing care after, 65
  squamous cell carcinoma, 260–263
Oribiloxacin, 294t
Orthovoltage teletherapy, 58
Osteosarcoma
  case example, 255
  chemotherapy, 70–71
  gonadectomy effect on risk, 10
  nursing highlights, 255
  overview of, 252
  pain management, 103–104, 103f
  staging, 252–253, 253f
  treatment, 254
Owners
  barriers to accepting or accessing treatment, 150
  cancer diagnosis, impact of, 135
  communicating with, 6–7, 142–146
  communication network, 145
  conflict, dealing with, 145–146
  improving communications, 143
  obstacles to communication, 145
  useful skills, 143–145, 144t
  complaints by, 151
  conflict between, 150
  disagreement with decisions of, 150
  euthanasia process and, 129–132
  grief and loss
    children, 141
    counseling, 141
    elderly owners, 141–142
    how nurses can help, 138–140
    memorials, 142
    reactions to, 137–138
    societal attitudes, 140
  human-animal bond, 135–136, 136f
  supporting, 135–146
Oxygen, nasal administration of, 162f
P
Packed cell volume (PCV), 161
Paclitaxel
toxicity
  anaphylaxis, 196, 196f
  hair loss, 76f
  hypersensitivity reactions, 75–76
  yew tree as source of, 91
Pain
  assessing in animals, 97, 101–102, 102t
  attitudes toward, in veterinary nursing, 99–100, 100t
  defined, 100, 101
  management/relief
    AAHA mandatory standards, 100
    with acupuncture, 91, 91f, 107
    after radiation therapy, 63, 65
    with alpha2-agonists, 106
    with bisphosphonates, 106
    in cats, 106
    complementary and alternative treatments, 107
    difficulties in, 107
    at home adaptive therapy, 106–107
    multimodal, 102–105, 103t
    nonpharmacologic therapy, 98, 103t, 106–107
    with NSAIDs (nonsteroidal antiinflammatory drugs), 103–106
    with opioids, 105, 105t, 106
    in osteosarcoma, 254–255
    pharmacologic analgesic therapy, 103t, 105–106, 105t
    roles of veterinary nurses in, 97–98, 98f, 99f
    modulation, 101
    pathologic, 101
    perception, 101
    physiologic, 101
    physiology of, 100–101
    scales, 101–102, 102t
    transduction, 101
    transmission, 101
Palliation
  as goal of treatment, 45
  palliative radiotherapy, 60, 62
Pamidronate
  in multimodal pain management, 104
  for osteoclast inhibition, 179, 192t
Pancyteopenia, 29, 161
Paraneoplastic syndrome
  hypercalcemia, 175
hypertrophic osteopathy, 218
with lymphoma in dogs, 229
Parathyroid adenoma, 176
Parathyroid hormone, 175–176
Parathyroid hormone-related protein (PTH-rP), 175
Parenteral feeding, 119–120
Partial parenteral nutrition (PPN), 120
Partial response, defined, 46t
Pathological fracture, 217–218
Pathology
  cytology, 17–19, 18f–19f
definition of terms, 16t
histopathology, 19–24, 20f–21f, 23f–24f
PCV (packed cell volume), 161
PDT (photodynamic therapy), 88
Pectin, 121
Pericardial effusion, 222–226
cardiac tamponade, 222, 224
causes, 222, 224
clinical features, 224
diagnosis, 223, 223f, 225
treatment/management, 223–224, 225
Pharynx, nursing care after radiation therapy, 65
PhaSeal system, 79, 79f, 82–83
Phosphorus
  hyperphosphatemia, 193t
tumor lysis syndrome (TLS), 190
Photodynamic therapy (PDT), 88
Photoirradiation, 88
Photosensitizer, 88
Physical examination, in staging of cancer, 27, 28f, 28t
Physical rehabilitation (physical therapy), 108–111
  active physical therapy, 109–110
    aquatic therapy, 110
    balance boards, 110
    cavaletti, 109–110
    dancing, 110
    incline/decline exercise, 109
    leash walking, 109
    physioballs and physiorolls, 110
  benefits, 108
defined, 108
goals, 108
limb function, assessment of, 108–109
  passive physical therapy, 111
cold therapy, 111
electrical stimulation (ES), 111
heat therapy, 111
therapeutic ultrasound, 111
Physioballs and physiorolls, 110
Pigmentation, change with radiation therapy, 62f, 63, 63f
Piroxicam, 86, 87, 103–104, 255, 261, 275–276, 290t
Platelets
  evaluation at time of myelosuppressive chemotherapy treatment, 73
  life span in circulation, 164
  postchemotherapy nadir of, 72
  thrombocytopenia, 29, 73, 164–169
Pollakiuria, 213
Polycythemia vera, 29
Potassium
  hyperkalemia, 190–191, 193t
  hypokalemia, 184–187, 193t
Potassium chloride, 185, 187, 193t
PPN (partial parenteral nutrition), 120
Prednisolone
  for anaphylaxis, 197, 198t
  for chronic lymphoid leukemia (CLL), 282, 283
  for hypercalcemia, 192t
  for hypoglycemia, 182, 184, 192t
  for lymphoma in cats, 238
  for lymphoma in dogs, 233
Privacy, respect for, 139, 151
Procarbazine
  drug information, 304–305
  for lymphoma in cats, 238
Professional boundaries, maintaining, 151
Prognosis
  communicating with owners, 6
definition of terms, 46t
  factors influencing, 6
  Kaplan-Meier survival curve, 47, 47f
Progressive disease, defined, 46t
Prostaglandins, inhibition by nonsteroidal antiinflammatory drugs (NSAIDs), 105–106
Pseudocapsule, 50
PTH-rP (parathyroid hormone-related protein), 175
Pulmonary carcinoma, 277–280
case example, 280
nursing highlights, 280
overview of, 277
risk factors for, 277
staging, 277–278, 278f, 280
treatment, 279, 279f
Quality of life, treatment goals and, 45–46
R
Radiation oncology, 8
Radiation therapy, 57–66
dose fractions, 61
effects of radiation
  acute, 60–61, 61f
  late, 61–62, 62f
  radiosensitive and radioresistant tissues, 60
goals of treatment, 60
nursing care, 60–66
  bone marrow, 65–66
  colon and rectum, 65
  ears, 63
  eyes, 63, 65f
  oral cavity and pharynx, 65
  skin, 62–63, 62f–64f
pain relief from, 104
for specific cancers
  lymphoma in cats, 238, 239
  mammary carcinoma in cats, 270–271
  mammary carcinoma in dogs, 267
  mast cell tumor, 242
  melanoma, 258
  oral squamous cell carcinoma, 261
  osteosarcoma, 254
  pulmonary carcinoma, 279
  soft tissue sarcoma (STS), 246
  transitional cell carcinoma (TCC), 276
types, 57–60
  brachytherapy, 59, 59f
  systemic therapy, 59–60
teletherapy, 58, 59f
Radical excisional surgery, 51–55
Radiography
- acute renal failure, 211–212
- anaphylaxis, 200
- anemia, 164
- disseminated intravascular coagulation (DIC), 160
- febrile neutropenia, 173
- hemangiosarcoma, 249f
- hematuria, 215
- hypercalcemia, 179
- hypertrophic osteopathy (HO), 183
- lymphoma in cats, 236, 237f
- lymphoma in dogs, 232–233, 232f
- mammary carcinoma in dogs, 265f, 268
- osteosarcoma, 253f
- pathologic fracture, 218
- pericardial effusion, 223, 223f, 225
- soft tissue sarcoma (STS), 244
- staging of cancer, 32, 32f, 33f, 34
- transitional cell carcinoma (TCC), 273, 274f

Radioresistant tissues, 60

Radiosensitive tissues, 60

Ranitidine, 117, 243, 293t

Rectum, nursing care after radiation therapy, 65

Rehabilitation. See Physical rehabilitation (physical therapy)

Remission, 233

Renal dysfunction
- acute renal failure, 208–212
- chemotherapy and, 26, 71, 208–209

Renewing tissues, 67

Rescue therapy, 234, 235

Restraint
- during chemotherapy, 78, 78f, 79
- during euthanasia, 129

pain management for cancer patients, 98, 98f, 99f

Retinoids, 85

Risk factors. See Causes of cancer in pets

Rottweiler, bone sarcoma in, 10

S

Safflower oil, 85–86

Saliva, artificial, 65

Samarium, 60, 104

Sarcoma. See also Hemangiosarcoma; Osteosarcoma;
- Soft tissue sarcoma (STS) defined, 5
- electron beam teletherapy for, 58, 59f
- histiocytic, 33f, 87
- radiographic evaluation of, 35f

Scar revision surgery, 50

SCC. See Squamous cell carcinoma (SCC)

Schistocytes, 158f, 161

Scintigraphy, 38

Scottish terrier, transitional cell carcinoma in, 10, 11

Self-care technicians, 152

Sepsis
catheter-induced, 127
- in disseminated intravascular coagulation (DIC), 160
- in neutropenia, 123–128, 170, 172, 174

Septic shock, 127, 170

Seroma, spread of cancer cells and, 48

Serum biochemistry panel, use in staging of cancer,
- 29–31
- alanine aminotransferase (ALT), 29–30
- albumin, 31
- alkaline phosphatase (ALP), 30
- bilirubin, 30
- calcium, 30–31
- creatinine, 30

Shock
- anaphylactic, 195
- septic, 127, 170

Siamese cat, genetic risk of cancers in, 10

Sigma receptors, 105

Skin
- hair and coat changes from chemotherapeutics, 76, 76f–77f
- radiation therapy, nursing care after, 62–63, 62f–64f

Sodium bicarbonate, for hyperkalemia, 191, 193t, 212

Sodium chloride
- for hypercalcemia, 179, 192t
- infiltration for vincristine extravasation injury, 207

Soft tissue sarcoma (STS)
- appearance, 245f, 246f
- case example, 247
- grading, 244–245
- injection site sarcoma (vaccine-associated sarcoma), 244
- nursing highlights, 247
- overview of, 244
- staging, 244–245, 246f, 247
- treatment, 246–247

Solid tumors, defined, 5

Spaying (ovariohysterectomy), effect on cancer risk, 10, 264, 267

Specialists, 7–8. See also specific specialties

Spiritual healing, 90

Spleen, hemangiosarcoma of, 248–251

Squamous cell carcinoma (SCC)
- nosectomy surgery for, 54–55, 55f
- oral, 260–263
- appearance of, 260, 261f
- case example, 263
- nursing highlights, 262
- overview of, 260
- staging, 260–261
- treatment, 261, 262f
- risk factors, 10, 11

Stable disease, defined, 46t

Staging of cancer, 25–40
- assessments used in process, 27–40
- bile acids, 39
- complete blood count (CBC), 27–29
- creatinine clearance, 38–39
- imaging, 32–38
- bone scintigraphy, 38
- computed tomography (CT), 34–36, 35f–38f
- magnetic resonance imaging (MRI), 35–36
- radiography, 32, 32f, 33f, 34
- ultrasonography, 34, 34f
- lymph node evaluation, 32
- MDR-1 gene (multiple drug resistance) test, 39
- physical examination, 27, 28f, 28t
- serum biochemistry panel, 29–31
- alanine aminotransferase (ALT), 29–30
- albumin, 31
- alkaline phosphatase (ALP), 30
- bilirubin, 30
- calcium, 30–31
- creatinine, 30

Stable disease, defined, 46t

Sodium bicarbonate, for hyperkalemia, 191, 193t, 212
globulin, 31

glucose, 31

urea, 30

urine evaluation, 31

veterinary bladder tumor antigen (V-BTA) test, 40

cancer type

chronic lymphoid leukemia (CLL), 281–282, 282f

hemangiosarcoma, 248, 249f, 250–251

lymphoma in cats, 237, 239

lymphoma in dogs, 231f, 233, 235

mammary carcinoma in cats, 269

mammary carcinoma in dogs, 264, 265f, 266–267, 266f, 268

mast cell tumor (MCT), 241–242, 241f, 243

melanoma, 256, 257f, 258

oral squamous cell carcinoma, 260–261

osteosarcoma, 254

pulmonary carcinoma, 279, 279f

soft tissue sarcoma (STS), 246

transitional cell carcinoma (TCC), 275

Surgical biopsy, 20

Surgical oncology, description, 7–8

Survival curve, Kaplan-Meier, 47, 47f

Syringes, Luer Lock, 80

Tamoxifen, 87

TCC. See Transitional cell carcinoma (TCC)

Tea solutions, for oral lavage, 65

Team, cancer-care

conflict within, 149

role of nurse in, 148–149

Technetium scintigraphy, 38

Teletherapy

electron beam, 58, 59f

megavoltage, 58

orthovoltage, 58

Terbutaline, for anaphylaxis, 199t

Test results, communicating with owners, 6

Thalidomide, 87

Therapeutic ultrasound, 111

Thrombocytopenia, 164–169

assessment before myelosuppressive therapy, 73

causes, 29, 124, 165, 166–167

in chronic lymphoid leukemia (CLL), 282

clinical features, 73, 167–168

defined, 165

diagnosis, 166, 168

treatment/management, 166, 168

Thrombopoi etin, 165

Thrombosis, 157. See also Disseminated intravascular coagulation (DIC)

Thyroid tumor

nutritional risk factors, 10

radioactive iodide treatment, 59–60

Ticarcillin-clavulanic acid, 294t

Tissue factor, 157

TLS. See Tumor lysis syndrome (TLS)

TNM system, of cancer staging, 25

Tobacco smoke, environmental (ETS), 10–12, 11f

Total parenteral nutrition (TPN), 119–120

“Touch-prints,” 17, 19, 19f

Toxicity and chemotherapy

cardiotoxicity, 73, 75t

gastrointestinal toxicity, 73

hair and coat changes, 76, 76f–77f

immune-mediated toxicity, 75–76

myelosuppression, 72–73

tissue differences, 67

urologic toxicity, 75

TPN (total parenteral nutrition), 119–120

Traditional Chinese medicine, 90

Tramadol, 63, 104, 106, 255, 291t

Transduction, pain, 101

Transfusion, 162, 250

Transitional cell carcinoma (TCC)

case example, 276

hematuria, 214

metastasis, 273, 275f

nursing highlights, 276

overview of, 273

risk factors, 10

seeding during surgery, 55
Index

staging, 273, 275f, 276
treatment, 275–276
ultrasonographic evaluation, 34f
veterinary bladder tumor antigen (V-BTA) test, 40
Transmissible venereal tumor, 68
Transmission, pain, 101
Treatment. See also specific cancers; specific modalities
biological response modification (BRM), 87–88
chemotherapy, 67–84
complementary and alternative medical (CAM) therapies, 90–93
goals, 45–46
photodynamic therapy (PDT), 88
radiation therapy, 57–66
response, evaluating, 46–46, 46f, 47f
surgery, 48–56
Trimethoprim-sulpha, 121
Trimethoprim-sulpha, 121, 126, 250, 294f
Trimetoprim-sulpha, 121
Tripelennamine, for anaphylaxis, 198f
Tumor lysis syndrome (TLS), 190–191
causes, 191
clinical features, 191
diagnosis, 190, 191
treatment/management, 190, 191
Tyrosine-kinase inhibitors, 88
U
Ulceration, gastric, 117, 243
Ultrasonography
acute renal failure, 211
anemia, 164
disseminated intravascular coagulation (DIC), 160
febrile neutropenia, 173
hemangiosarcoma, 248, 249f, 250–251
hematuria, 215
hypercalcemia, 179
hypoglycemia, 183
lymphoma in cats, 236, 239
lymphoma in dogs, 232–233
pericardial effusion, 223, 223f
staging of cancer, 34, 34f
therapeutic, 111
thrombocytopenia, 168
transitional cell carcinoma (TCC), 273, 274f, 276
Urea, evaluation in staging of cancer, 30
Urine evaluation, for staging of cancer, 31
Urine evaluation, for staging of cancer, 31
Urinary tract infection, 31, 273, 276
Urinary tract infection, 31, 273, 276
Urinary tract infection, 31, 273, 276
Urinary tract infection, 31, 273, 276
Urine evaluation, for staging of cancer, 31
Urologic toxicity
calcium nephropathy, 177, 208
of chemotherapeutics, 75
Urological emergencies, 208–216
acute renal failure, 208–212
hematuria, 213–216
Urothelial toxicity, 75
V
Vaccination
delaying for chemotherapy, 72
DNA, 88
Vaccine-associated sarcoma, 244
Vascular endothelial growth factor (VEGF), antibody to, 87
Vertical laminar flow hood, 80, 81f
Vesicants, 202
Veterinary Anesthesia and Analgesic Support Group, 100
Veterinary bladder tumor antigen (V-BTA) test, 40
Vicarious trauma, 153
Vinblastine, 305
Vincristine
drug information, 305
for lymphoma in cats, 238
for lymphoma in dogs, 233
periwinkle plant as source of, 91
toxicity
extravasation injury, 202–205, 203f, 207
gastrointestinal, 121
for transmissible venereal tumor, 68
Vinorelbine, 305
Viral infection, thrombocytopenia from, 165, 167
Vomiting, antiemetics for, 116
W
Waste disposal, chemotherapy and, 82, 82, 83–84
Weight, conversion to body surface area (BSA), 287–289f
World Health Organization (WHO), 25
X
Xerostomia, 65